Interestingly, when we considered Cdt1 and Cdc6 together, patients whose breast cancer expressed both Cdt1 and Cdc6 at a high level had a significantly shorter survival time compared to those patients whose breast cancer expressed only one of Cdc6 or Cdt1 at a high level (Wilcoxon-Gehan test, p = 0.01), or those patients whose breast cancer expressed both Cdc6 and Cdt1 at a low level (Wilcoxon-Gehan test, p < 0.001; Fig. 3D). This evidence concerns the gene CDC6 and breast carcinoma.